The Centers for Disease Control and Prevention announced Thursday that it will convene an "emergency meeting" of its advisers on June 18th to discuss rare but higher-than-expected reports of heart inflammation following doses of the mRNA-based Pfizer and Moderna COVID-19 vaccines.
Shimabukuro said their findings were mostly "consistent" with reports of rare cases of heart inflammation that had been studied in Israel and reported from the U.S.
The CDC is working on more data and analysis on the reports ahead of the emergency meeting of its own advisers next week, he said, and also planned to analyze the risk of heart inflammation posed by catching COVID-19.
The new details about myocarditis and pericarditis emerged first in presentations to a panel of independent advisers for the Food and Drug Administration, who are meeting Thursday to discuss how the regulator should approach emergency use authorization for using COVID-19 vaccines in younger children.
The CDC previously disclosed that reports of heart inflammation were detected mostly in younger men and teenage boys following their second dose, and that there was a "higher number of observed than expected" cases in 16- to 24-year-olds.
Marion Gruber, director of the FDA's vaccine office, said at the meeting
UK
Australia
France
Germany
Russia
India
Canada